Sildenafil: A new oral therapy for erectile dysfunction

Mark Bradley Noss, George J. Christ, Arnold Melman

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations

Abstract

Sildenafil citrate (Viagra®) is a relatively selective 5- phosphodiesterase (PDE) inhibitor. It is the first oral medication approved for the treatment of erectile dysfunction (ED). The neuronal release of NO which binds to the heme-containing region of guanylate cyclase increases levels of cGMP. This leads to a cascade of reaction which results in corporal smooth muscle relaxation and penile erection. Sildenafil causes an erection by inhibiting PDE5, which is turn causes an increase in the intracellular levels of cGMP. Sildenafil is well absorbed after a single oral administration with a t 1/2 of approximately 4 h. The mode of onset varies from 0.5-4 h. The drug has been used in millions of men since first approved by the U.S. FDA 1 year ago and has revolutionized the approach to, and therapy of, erectile dysfunction.

Original languageEnglish (US)
Pages (from-to)211-217
Number of pages7
JournalDrugs of Today
Volume35
Issue number3
DOIs
StatePublished - Mar 1999

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Sildenafil: A new oral therapy for erectile dysfunction'. Together they form a unique fingerprint.

Cite this